Most Read Articles
2 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.

Periprocedural bridging in VTE patients tied to greater bleeding incidence

10 Jul 2019

Compared with vitamin K antagonist (VKA) without bridging, periprocedural bridging is associated with a higher risk of bleeding, with no significant difference in periprocedural venous thromboembolism (VTE) rates, results of a systematic review have shown.

This study sought to examine recurrent VTE and bleeding outcomes with and without bridging in patients with previous VTE due to the uncertain benefits and risks of periprocedural bridging in this population.

The investigators searched the PubMed and Embase databases from inception to 7 December 2017 for randomized and nonrandomized studies that included adults with previous VTE requiring VKA interruption to undergo an elective procedure and that reported VTE or bleeding outcomes. Quality of evidence was graded by consensus.

Twenty-eight cohort studies (20 single-arm cohorts) with a total of 6,915 procedures were analysed. In 27 studies reporting perioperative VTE outcomes, recurrent VTE with bridging had a pooled incidence of 0.7 percent (95 percent CI, 0.4–1.2 percent), while that in recurrent VTE without bridging was 0.5 percent (0.3–0.8 percent).

In 18 studies, major or nonmajor bleeding outcomes were reported. The corresponding pooled incidence of any bleeding for with and without bridging was 3.9 percent (2.0–7.4 percent) and 0.4 percent (0.1–1.7 percent). The pooled incidence for VTE in bridged patients at high thromboembolic risk was 0.8 percent (0.3–2.5 percent) and 7.5 percent (3.1–17.4 percent) for any bleeding.

Due to a high risk of bias among included studies, the quality of available evidence was very low.

“VKA are the most widely used anticoagulants, and bridging is commonly administered during periprocedural VKA interruption,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.